Best time for reperfusion in acute pulmonary embolism
Official title: Optimal Time for Reperfusion in Acute Pulmonary Embolism
Run by Azienda ULSS 8 Berica · NCT07436702 · Data updated 2026-11-12
This study will test whether performing reperfusion (systemic thrombolysis or catheter‑directed therapy) earlier improves survival and reduces complications in adults with high‑risk or intermediate‑high‑risk pulmonary embolism.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 500 (estimated) |
| Sponsor | Azienda ULSS 8 Berica Academic / other |
| Locations | 7 sites (Milan, Milano and 6 other locations) |
| Status | Recruiting |
| Started | November 25, 2025 |
| Main results expected | October 30, 2026 |
| Study ends | October 30, 2026 |
| Registry record updated | March 3, 2026 |
| Trial ID | NCT07436702 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with imaging‑confirmed high‑risk or intermediate‑high‑risk pulmonary embolism who can provide informed consent and are treated at participating centers.
✕Probably not a fit
Patients with low‑risk PE, chronic stable PE, those who cannot receive reperfusion therapies, or those treated outside participating centers are unlikely to receive direct benefit from this study's findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a national, multicenter, prospective observational study enrolling adults with imaging‑confirmed high‑risk or intermediate‑high‑risk pulmonary embolism at participating Italian centers. Investigators will record timing from symptom onset and hospital admission to reperfusion with systemic thrombolysis or catheter‑directed therapies and track in‑hospital mortality as well as hemorrhagic and cardiovascular complications. Time‑to‑treatment analyses will be used to identify temporal cutoffs associated with better outcomes while accounting for comorbidities and bleeding risk. The goal is to provide evidence on whether a specific reperfusion time window is associated with improved short‑term clinical outcomes.
Why it matters
Potential benefit: If successful, defining an optimal reperfusion time window could increase survival and reduce hemodynamic collapse and bleeding by guiding earlier treatment decisions.
How similar studies have gone: Systemic thrombolysis and catheter‑directed therapies are established for selected high‑risk PE, but prospective, multicenter evidence specifically defining optimal timing is limited and largely untested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Patients with a diagnosis of intermediate-high or high pulmonary embolism confirmed by computed tomography pulmonary angiography (CTPA), pulmonary angiography, or echocardiography (evidence of a floating thrombus in the right atrium or right ventricle, or proximal visualization of thrombus in the pulmonary artery). * Classified as high-risk or intermediate-high-risk according to the 2019 European Society of Cardiology guidelines. * Provision of informed consent for the processing of personal data. Exclusion Criteria: * Age \< 18 years * Patients in whom a diagnosis of acute high-risk or intermediate-high-risk pulmonary embolism has been excluded. * Inability to provide informed consent.
Where it's running
-
UO Unità di Cure Intensive Cardiologiche e Cardiologia 1, Ospedale Niguarda, Milano
Milan, Milano, Italy Recruiting -
UOC di Cardiologia, Ospedali Riuniti Padova Sud, Monselice, Italia
Monselice, Padova, Italy Recruiting -
IRCCS Policlinico San Matteo
Pavia, Pavia, Italy Recruiting -
UO di Sezione di Medicina Interna e Cardiovascolare, Ospedale Santa Maria della Misericordia, Perugia, Italia
Perugia, Perugia, Italy Recruiting -
UO di Cardiologia 1, Azienda Ospedaliero Universitaria Pisana, Pisa, Italia
Pisa, Pisa, Italy Recruiting -
UO di Cardiologia, Azienda Ospedaliera Ordine Mauriziano di Torino
Torino, Torino, Italy Recruiting
Show 1 more location
-
UOC di Cardiologia, Ospedali dell'Ovest Vicentino, Arzignano, IItalia
Arzignano, Vicenza, Italy Recruiting
Study contacts
- Principal investigator: Claudio Bilato, MD PhD — Department of Cardiology, Azienda AULSS 8 Berica, Arzignano (Vicenza), Italy
- Study coordinator: Claudio Bilato, MD PhD
- Email: claudio.bilato@aulss8.veneto.it
- Phone: +390444479106
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Non-contrast CT V: See If CT has a Role in Finding Pulmonary Embolism
This study tests whether additional low-dose, non-contrast CT scans can help detect pulmonary embolism in patients who are already being evaluated for suspected PE.
-
Repeated exams to classify early pulmonary embolism
This project will test whether doing repeated blood tests, ECGs, and bedside heart ultrasounds during the first 48 hours after pulmonary embolism helps predict who will get worse in adults treated at Sahlgrenska University Hospital.
-
Heart@Home: Safe, at-home care for people with acute heart problems compared with hospital care
This trial tests whether hospital-level care at home can safely and effectively treat adults with acute heart conditions who would normally be in the hospital.
-
Lung perfusion scans in ED patients with suspected pulmonary embolism
This study looks at how lung perfusion (and sometimes ventilation) scans in adults with suspected pulmonary embolism seen in the emergency department influence clinical decisions and patient outcomes.
-
Thromboelastometry to Predict Thrombosis and Survival in Glial Tumor Surgery
Aimed at people with glial tumors undergoing surgery, the study tests whether thromboelastometry and other blood tests can predict blood-clot risk and survival.
-
Pulsatile Electrical Impedance Tomography to Diagnose and Monitor Acute Pulmonary Embolism
This study tests whether bedside pulsatile electrical impedance tomography can help diagnose and track acute pulmonary embolism without radiation.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.